Learn More
IRF8 Monoclonal Antibody (V3GYWCH), PE, eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
Brand: Invitrogen 12-9852-82
Description
Description: The V3GYWCH monoclonal antibody reacts with human and mouse interferon regulatory factor 8 (IRF8; ICSBP). IRF8 is a 50 kDa transcription factor that plays a critical role in the development of dendritic cells (DC). Specifically, IRF8 is essential in the development and differentiation of plasmacytoid DC (pDC) and CD8a+ DC. IRF8-/- mice are deficient in both pDC and CD8a+ DC populations. CD8a- DC are present in normal numbers in IRF8-/- mice but fail to mature upon Toll-like receptor signaling and are functionally impaired in response to in vivo microbial stimulation. IRF8 deficiency does not affect the frequency or viability of DC precursors and as a result retroviral IRF8 transduction restores pDC development from DC progenitors in IRF8-/- mice. Applications Reported: This V3GYWCH antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This V3GYWCH antibody has been tested by intracellular staining and flow cytometric analysis of normal human peripheral blood cells using the Foxp3/Transcription Factor Staining Buffer Set (cat. 00-5523) and protocol. Please refer to Best Protocols: Protocol B: One-step protocol: intracellular (nuclear) proteins located under the Resources Tab online. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL.
IRF8 (interferon regulatory factor 8) is a transcriptional activator or repressor. It specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes. IRF8 plays a negative regulatory role in cells of the immune system. It is involved in CD8+ dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells. This leads to recognition of AICE sequence, an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of the genes. Mutations in the gene can result in immunodeficiencey 32A and 32B.Specifications
IRF8 | |
Monoclonal | |
0.2 mg/mL | |
PBS with 0.09% sodium azide; pH 7.2 | |
P23611, Q02556 | |
Irf8 | |
Affinity chromatography | |
RUO | |
15900, 3394 | |
4° C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
V3GYWCH | |
PE | |
Irf8 | |
AI893568; H-ICSBP; Icsbp; Icsbp1; IMD32A; IMD32B; interferon consensus sequence binding protein 1; Interferon consensus sequence-binding protein; Interferon regulatory factor 8; Irf8; IRF-8; Myls; transcription factor ICSBP | |
Mouse | |
100 μg | |
Primary | |
Human, Mouse | |
Antibody | |
IgG1 κ |
For Research Use Only.